Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
Not enough history yet.
US$ billions, as reported in each year's annual results.
Revenue of the fiscal year. US dollars at each year's exchange rate.
| Measure | Neuraxis, Inc.✕ NRXS · #18,885 in the world |
|---|---|
| Profile | |
| Country | 🇺🇸 USA |
| Sector | Healthcare |
| Industry | Medical Devices |
| Founded | — |
| Size | |
| Market cap | $95 M |
| Revenue | $4 M |
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | Neuraxis, Inc. |
|---|---|
| 2025 | $4 MSEC |
| 2024 | $3 MSEC |
| 2023 | $2 MSEC |
| 2022 | $3 MSEC |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| $-8 M |
| Employees | 24 |
|---|
| Valuation | |
|---|---|
| Price to sales | 14.6× |
| Price to book | 28.1× |
| Free cash flow yield | -6.8% |
| Profitability | |
|---|---|
| Gross margin | 84.3% |
| Operating margin | -219.3% |
| Net margin | -218.5% |
| Return on equity | -285.2% |
| Growth | |
|---|---|
| Revenue growth | 32.7% |
| Revenue growth, 3 years a year | 10.0% |
| Financial strength | |
|---|---|
| Interest cover | -111.9× |
| Cash | |
|---|---|
| Free cash flow margin | -180.9% |
| Altman Z-score zone | grey |
|---|
| Data as of | Market cap Oct 2026; ratios FY2025 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.